Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Memantine for Prevention of Alzheimer's Disease
NCT05063851Phase 2Active, not recruiting
- Sponsor
- University of Virginia
- Start
- Oct 2021
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing Memantine hydrochloride with Placebo (2 arms). Primary endpoint: Percentage of patients who are lost to follow-up at 24 months. Started Oct 2021; status: active, not recruiting.
02
Drugs
memantine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05063851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063851.